期刊
DIABETES CARE
卷 42, 期 6, 页码 1147-1154出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc18-2316
关键词
-
资金
- ATTD Congress
- Boehringer Ingelheim
- Sanofi
- Eli Lilly
- Roche
- Medtronic
- Eli Lilly and Company
- Johnson Johnson
- Merck
- Abbott
- MannKind
- AstraZeneca
- Elcelyx Therapeutics
- Intarcia Therapeutics
- vTv Therapeutics
- AstraZeneca HealthCare Foundation
- National Institutes of Health
- Novo Nordisk
- Merck Sharp Dohme
- Novartis
- Janssen Pharmaceuticals
- Hanmi Pharmaceuticals
- Pfizer
- UCB
- KU Leuven
- Insulet, and Senseonics
- Bayer
- Boehringer
- Bayer Health Care
- NovoNordisk
- GluSense
- GlaxoSmithKline
- LifeScan
- Servier
- Intarcia
- Eli Lilly/Boehringer Ingelheim
- Becton Dickinson
- Regeneron Pharmaceuticals, Inc.
- Amgen
- AbbVie
- TanabeMitsubishi
- Takeda Pharmaceuticals
- ViaCyte
- Insulet, Johnson Johnson
- Roche Diabetes Care, and Senseonics
- Roche Diagnostics
- Regeneron
- JDRF
- Leona M. and Harry B. Helmsley Charitable Trust
- Esperion
- National Institutes of Health, JDRF
- Diabetes Research Institute Foundation
- European Union INNODIA consortium
- Moerae Matrix
- DaiichiSankyo
- Kowa
- Kyowahakko-Kirin
- Ono
- Taisho-Toyama
- Takeda
Sodium-glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据